NCT01220232View on ClinicalTrials.gov

Estimate The Effect Of Lersivirine On The Pharmacokinetics Of Abacavir/Lamivudine In Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

November 30, 2010

Primary Completion Date

January 31, 2011

Study Completion Date

January 31, 2011

Conditions
Healthy Volunteers
Interventions
DRUG

Abacavir/Lamivudine

Abacavir/Lamivudine 600/300 mg QD for 5 days

DRUG

Abacavir/Lamivudine

Abacavir/Lamivudine 600/300 mg QD for 10 days

DRUG

Lersivirine

Lersivirine 750 mg QD for 10 days

Trial Locations (1)

06511

Pfizer Investigational Site, New Haven

Sponsors

Lead Sponsor

Pfizer

Collaborators (1)

ViiV Healthcare
All Listed Sponsors
collaborator

ViiV Healthcare

INDUSTRY

lead

Pfizer

INDUSTRY

NCT01220232 - Estimate The Effect Of Lersivirine On The Pharmacokinetics Of Abacavir/Lamivudine In Healthy Subjects | Biotech Hunter | Biotech Hunter